Selzentry Oral Tablet 150Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Selzentry: Oral tablet (150mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_16529.JPG
Selzentry 150mg Tablet
ViiV Healthcare a GSK and Pfizer Company
Pill Identification: MVC 150 
Drug Image file default-drug-image.png
Selzentry 150mg Tablet

What is this Medicine?

MARAVIROC (mah RAV er rock) is an antiretroviral medicine. It is used with other medicines to treat HIV. This medicine is not a cure for HIV. It will not stop the spread of HIV to others.

CVS Pharmacy Patient Statistics for Selzentry: Oral tablet(150mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information
Select a Medication

Selzentry 150mg Tablet

NDC: 497020223
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Human Immunodeficiency Virus (HIV) Infection

Sometimes used for but not FDA approved for the following conditions:
Human Immunodeficiency Virus (HIV) Prophylaxis

Storage Information
Store between 68 to 77 degrees F, excursions permitted 59 to 86 degrees F
Selzentry 150mg Tablet
Drug Image file DrugItem_16529.JPG
ViiV Healthcare a GSK and Pfizer Company
Pill Identification: MVC 150 
Shape: oval
Color: blue

Reported Side Effects for Selzentry 150mg Tablet

Shaking Incidence:
<2.0%*
Severity: MILD
Onset: EARLY
Secondary Malignancy Incidence:
<3.0%*
Severity: MODERATE
Onset: DELAYED
Pseudomembranous Colitis Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Liver Disease Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Brain Infection Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Brain Attack Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Yellow Skin Incidence:
<2.0%*
Severity: MODERATE
Onset: DELAYED
Heart Failure Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Liver Failure Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Breakdown Of Muscle Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Blood Clot Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Visual Impairment Incidence:
<2.0%*
Severity: SEVERE
Onset: EARLY
Dead Bone Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Chest Pain Incidence:
<2.0%*
Severity: MODERATE
Onset: EARLY
Anemia Incidence:
<8.0%*
Severity: MODERATE
Onset: DELAYED
Convulsions Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Postural Low Blood Pressure Incidence:
0.5%*
Severity: MODERATE
Onset: DELAYED
Heart Attack Incidence:
0.8-1.3%*
Severity: SEVERE
Onset: DELAYED
Conjunctivitis Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Eye Infection Incidence:
2.0%*
Severity: MODERATE
Onset: DELAYED
Flu Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Skin Redness Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Hair Loss Incidence:
2.0%*
Severity: MILD
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
2.6-4.8%*
Severity: MODERATE
Onset: DELAYED
Ejaculation Dysfunction Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Fat Redistribution Incidence:
3.0-4.0%*
Severity: MODERATE
Onset: DELAYED
Decreased Memory Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Acne Incidence:
3.0%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
3.0%*
Severity: MODERATE
Onset: EARLY
Muscle Pain Incidence:
3.0%*
Severity: MILD
Onset: EARLY
Nervousness Incidence:
4.0%*
Severity: MILD
Onset: DELAYED
Depression Incidence:
4.0%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
4.0%*
Severity: MODERATE
Onset: EARLY
Paresthesias Incidence:
4.0-5.0%*
Severity: MILD
Onset: DELAYED
Inflamed Hair Follicles Incidence:
4.0%*
Severity: MILD
Onset: DELAYED
Nerve Pain Incidence:
4.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
4.0%*
Severity: MILD
Onset: RAPID
Stuffy Nose Incidence:
4.0%*
Severity: MILD
Onset: EARLY
Dysesthesia Incidence:
4.0-5.0%*
Severity: MILD
Onset: DELAYED
High Amylase Levels Incidence:
4.3-5.7%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
4.3-5.7%*
Severity: MODERATE
Onset: DELAYED
High Bilirubin Level Incidence:
5.5%*
Severity: MODERATE
Onset: DELAYED
Constipation Incidence:
6.0%*
Severity: MODERATE
Onset: DELAYED
Joint Pain Incidence:
6.0-7.0%*
Severity: MILD
Onset: DELAYED
Sinus Infection Incidence:
7.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
8.0-9.0%*
Severity: MILD
Onset: EARLY
Inability To Sleep Incidence:
8.0%*
Severity: MILD
Onset: EARLY
Gas Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
11.0%*
Severity: MILD
Onset: EARLY
Fever Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
14.0%*
Severity: MILD
Onset: DELAYED
Infection Incidence:
55.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Selzentry 150mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Selzentry 150mg Tablet(Maraviroc)
Grapefruit juice and Maraviroc(Maraviroc)
Do not drink large amounts of grapefruit juice without first talking to your health care provider. Grapefruit juice may increase the actions of maraviroc. The dose of maraviroc will need to be decreased if you drink large amounts of grapefruit Juice.
Pregnancy & Lactation Information
FIRST Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

SECOND Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

THIRD Trimester

Class B - Animal studies have revealed no evidence of harm to the fetus, however, there are no adequate and well-controlled studies in pregnant women. OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Selzentry

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5